An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy

Trial Profile

An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Cerebroside-sulfatase (Primary)
  • Indications Metachromatic leukodystrophy
  • Focus Adverse reactions
  • Sponsors Shire
  • Most Recent Events

    • 21 Aug 2015 Protocol has been amended to change in treatment arms.
    • 21 Aug 2015 Planned End Date changed from 1 Feb 2018 to 1 Oct 2021 as reported by ClinicalTrials.gov record.
    • 21 Aug 2015 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2021 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top